Stenabolic is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
== History == The neurotoxin was reported in 1983 when researchers studied the snake venom for their effects on neuromuscular transmission. Since then, it has contributed to the knowledge about synaptic transmission, cholinergic synapses, and nicotinic acetylcholine receptors (nAChRs). κ-Bungarotoxin is still widely used in research due to its specificity to various nAChRs. The toxin got the kappa in its name as reference to the Latin word kiliaris, which means "related to the eye", from which the ciliary ganglion got its name. Two toxins, named "toxin F" and "bungarotoxin 2.1" were identified by protein sequencing the same way as κ-bungarotoxin.
== Mirin kasu nutrition == Mirin kasu contains water, alcohol, fat, carbohydrate, and protein. A type of protein called resistant protein can be found in Mirin kasu. Resistant protein is beneficial to the consumers' health because it can improve immunity against lifestyle-related diseases including tumorigenesis, gallstone formation, corpulence hypercholesterolemia, constipation, and improving enteric fermentation of short-chain fatty acids.
=== EC 2.2.1: Transketolases and Transaldolases === EC 2.2.1.1: transketolase EC 2.2.1.2: transaldolase EC 2.2.1.3: formaldehyde transketolase EC 2.2.1.4: acetoin—ribose-5-phosphate transaldolase EC 2.2.1.5: 2-hydroxy-3-oxoadipate synthase EC 2.2.1.6: acetolactate synthase EC 2.2.1.7: 1-deoxy-D-xylulose-5-phosphate synthase EC 2.2.1.8: fluorothreonine transaldolase EC 2.2.1.9: 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylic-acid synthase EC 2.2.1.10: 2-amino-3,7-dideoxy-D-threo-hept-6-ulosonate synthase EC 2.2.1.11: 6-deoxy-5-ketofructose 1-phosphate synthase EC 2.2.1.12: 3-acetyloctanal synthase EC 2.2.1.13: apulose-4-phosphate transketolase EC 2.2.1.14: 6-deoxy-6-sulfo-D-fructose transaldolase
=== Brady === In February 2019, the trial of Mikel Brady was scheduled for October 7, 2019, making Brady the first of the four set to stand trial for the 2017 prison attack. On October 21, 2019, Brady was found guilty of all four counts of first degree murder and ten other lesser charges, including attempted escape, assault with a deadly weapon and arson. The offence of first degree murder carries a sentence of either life imprisonment without the possibility of parole or the death penalty under North Carolina state law. During the sentencing trial, the defence argued for Brady to be sentenced to life imprisonment, citing the details of Brady's troubled childhood and past medical history of his psychiatric conditions. Brady's lawyer, Thomas Manning, summarized Brady's childhood into a poem, "As the twig is bent, so goes the tree". On the other hand, the prosecution sought the death penalty, with District Attorney Andrew Womble citing the brutality of the attack and aggravating factors in the case. Womble also quoted that if the jury settled on life imprisonment, "it will be open season on corrections officers in this state." On October 28, 2019, 30-year-old Mikel Brady was sentenced to death upon the jury's unanimous recommendation for capital punishment, making Brady the 143rd inmate to be condemned to death row in North Carolina; a total of 142 inmates were held on death row in North Carolina at the time of Brady's sentencing. After he was sentenced to death, Brady was at first held on death row at the Central Prison in Raleigh, North Carolina.
Sources: en.wikipedia.org
=== 1918 uprisings === In mid-1918, the Union moved from underground organization to open insurrection. It played a central role in organizing a series of anti-Bolshevik uprisings, most notably in Yaroslavl, but also in Rybinsk, Murom, and Elatma. These uprisings formed part of a broader effort to ignite coordinated resistance against the Bolshevik government. Additional revolts were reportedly planned in Moscow and Kazan, but arrests of members of the organization in May 1918 disrupted these plans before they could be carried out. The uprisings were suppressed by Soviet forces, and the Union's operational structure inside Russia was effectively broken apart in the aftermath.
The Gallop Ministry was the 33rd Ministry of the Government of Western Australia, and was led by Labor Premier Geoff Gallop and his deputy, Eric Ripper. It succeeded the Court–Cowan Ministry on 16 February 2001, following the defeat of the Liberal-National coalition government at the 2001 election six days earlier. The Ministry was reconstituted on 10 March 2005 following the February 2005 election. It was succeeded by the Carpenter Ministry on 3 February 2006 due to the retirement of Geoff Gallop from politics on 25 January.
Glutathione + Isopentenyl Pyrophosphate → 3-MBG 3-MBG + γ-GTP → MBCG MBCG + Cauxin → Felinine + Glycine, or MBCG → N-Acetylfelinine Urine of domestic cats may contain a series of felinine-containing compounds including free felinine, acetylfelinine, felinylglycine and 3-MBG. Cysteine also plays a role in the synthesis of felinine. For one, the amino acid is commonly present in many enzymes. Also, it is one of the few precursors for glutathione. Glutathione is converted to 3-MBG, and so cysteine has an important role in the early steps of synthesis.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.